PSMA CAR Antigen-Binding Domains for Stronger T-Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing chimeric antigen receptors (CARs) targeting prostate-specific membrane antigen (PSMA) for cancer treatment do not possess optimal properties for effective immunotherapy.
Innovation Solution
Development of novel antigen-binding domains with specific complementarity determining regions (CDRs) for PSMA targeting, including heavy and light chain variable regions, and single-domain antibodies, which are integrated into chimeric antigen receptors (CARs) to enhance T-cell activation and targeting efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antigen-binding domains are used in CARs targeting PSMA, then the CAR structure is simpler and easier to manufacture, but the binding affinity and T-cell activation efficacy are insufficient
Solution Approach 1:
The patent combines multiple antigen-binding domain formats (scFv, Fab, single-domain antibodies) with different spacer lengths and transmembrane domains to create composite CAR structures. This composite approach allows optimization of binding affinity and T-cell activation while maintaining structural feasibility for manufacturing and clinical application.
Solution Approach 2:
The patent systematically varies key parameters including spacer length (short vs. long), antigen-binding domain type (scFv, Fab, single-domain), and transmembrane domain composition to optimize CAR performance. These parameter changes enable fine-tuning of binding affinity and activation efficacy without fundamentally redesigning the entire CAR architecture.
2Productivity
If antigen-binding domains with optimized CDRs are developed for PSMA targeting, then the therapeutic efficacy against cancer cells is enhanced, but the development time and complexity increase
Solution Approach 1:
The patent performs preliminary optimization of complementarity-determining regions (CDRs) through in silico modeling and in vitro selection before final CAR construction. This preliminary action on CDR sequences accelerates the development process by pre-identifying high-affinity binding regions, reducing the need for extensive iterative testing while maintaining high therapeutic efficacy.
Solution Approach 2:
The patent develops antigen-binding domains with universal applicability across multiple cancer types expressing PSMA (prostate, kidney, breast, colon cancers). By creating multi-functional binding domains that can target PSMA in various tumor contexts, the development time is reduced through platform technology rather than developing separate solutions for each cancer type.
3Measurement precision
If novel antigen-binding domains with specific CDRs are integrated into CARs, then the specificity and activation of T-cells is improved, but the manufacturing complexity increases
Solution Approach 1:
The patent segments the CAR construct into distinct modular components: antigen-binding domain (with optimized CDRs), spacer region, transmembrane domain, and intracellular signaling domain. This segmentation allows each component to be independently optimized for specificity while being manufactured separately and assembled through standard molecular biology techniques, reducing overall manufacturing complexity.
Solution Approach 2:
The patent applies local quality optimization by focusing CDR optimization efforts specifically on the antigen-binding domain while using standardized, well-characterized sequences for spacer, transmembrane, and signaling regions. This localized approach to optimization maintains high PSMA-specificity where needed while simplifying manufacturing through standardization in other regions.
Data Source
AI summary
The present disclosure relates to antigen-binding domains which bind the antigen prostate-specific membrane antigen (PSMA) and to chimeric antigen receptors (CARs) which comprise such antigen binding domains.